



# A novel murine CTP:phosphoethanolamine cytidyltransferase splice variant is a post-translational repressor and an indicator that both cytidyltransferase domains are required for activity



Zvezdan Pavlovic\*, Ratnesh Kumar Singh, Marica Bakovic

Department of Human Health and Nutritional Sciences, University of Guelph, 50 Stone Road East, Guelph, Ontario N1G2W1, Canada

## ARTICLE INFO

### Article history:

Received 10 December 2013

Received in revised form 20 March 2014

Accepted 1 April 2014

Available online 3 April 2014

### Keywords:

Phosphatidylethanolamine

Kennedy pathway

Phospholipids

Dimerization

Dominant negative

## ABSTRACT

CTP:phosphoethanolamine cytidyltransferase (Pcyt2) has an important regulatory function in biosynthesis of the membrane phospholipid phosphatidylethanolamine. We previously determined that the full-length Pcyt2 $\alpha$  and its splice variant Pcyt2 $\beta$  are the main active isoforms of this enzyme. Here we report that mouse Pcyt2 could be spliced at Introns 7 and 8 to produce a unique third isoform, Pcyt2 $\gamma$ , in which the second cytidyltransferase domain at the C-terminus becomes deleted. Pcyt2 $\gamma$  is ubiquitously expressed in embryonic and adult mouse tissues, and is the most abundant in the kidney, skeletal muscle and testis. Pcyt2 $\gamma$  splicing mechanism dominates over Pcyt2 $\beta$  exon-skipping mechanism in most examined tissues. Although Pcyt2 $\gamma$  maintains the N-terminal cytidyltransferase domain as most cytidyltransferases, the lack of the C-terminal cytidyltransferase domain causes a complete loss of catalytic activity. However, Pcyt2 $\gamma$  interacts with the active isoform, Pcyt2 $\alpha$ , and significantly reduces Pcyt2 $\alpha$  homodimerization and activity. The inactive N-domain (H35Y, H35A) and C-domain (H244Y, H244A) mutants of Pcyt2 $\alpha$  also reduce Pcyt2 $\alpha$  homodimerization and activity. This study revealed the importance of both cytidyltransferase <sup>35</sup>HYGH and <sup>244</sup>HIGH motifs for the activity of murine Pcyt2 $\alpha$  and established that the naturally occurring splice variant Pcyt2 $\gamma$  has a function to restrain the enzyme activity through the formation of unproductive enzyme complexes.

© 2014 Elsevier B.V. All rights reserved.

## 1. Introduction

CTP:phosphoethanolamine cytidyltransferase (Pcyt2) plays an important regulatory role in de novo biosynthesis of phosphatidylethanolamine (PE) by the CDP-ethanolamine (Kennedy) pathway. The Kennedy pathway is initiated by ethanolamine kinase (EK) that phosphorylates ethanolamine to produce phosphoethanolamine (P-Etn). The subsequent reaction between P-Etn and CTP is mediated by Pcyt2 and results in the production of CDP-ethanolamine (CDP-Etn) and pyrophosphate. The final step of the pathway is carried out by CDP-ethanolamine:1,2-diacylglycerol ethanolaminephosphotransferase (EPT) to produce PE from CDP-Etn and diacylglycerol. PE is the most abundant lipid in the cytoplasmic leaflet of cellular membranes. It has

important roles in cellular processes including protein folding and lipidation (Deleault et al., 2012; Girardi et al., 2011; Pereira et al., 2012), membrane fusion (Deeba et al., 2005), cell cycle (Emoto et al., 1996), autophagy (Ichimura et al., 2000; Pereira et al., 2012), and apoptosis (Emoto et al., 1997). We recently reviewed the most current state of knowledge on the regulatory role of Pcyt2 in PE homeostasis and pathologies including the metabolic syndrome and cancer (Pavlovic and Bakovic, 2013).

Alternative splicing is considered to be the most plausible explanation for the apparent paradox that evolutionary distinctive organisms resemble in the number of their gene products. There are four major types of alternative splicing: exon-skipping, alternative usage of 5'-donor site or 3'-acceptor site and intron-retention (Galante et al., 2004). The most frequent splicing mechanism is the exon-skipping while the intron-retention represents the least established mechanism (Galante et al., 2004). There are also many examples of alternative splicing in which two or more donor splice sites compete for a single acceptor site (Eperon et al., 2000). Intron-retention and usage of an alternative donor splice site can cause a frame-shift and the formation of a premature stop-codon; this will generate a truncated protein product that can interfere with normal protein function (Gervois et al., 1999; Kim et al., 2006; Lundell et al., 2007). There are numerous examples of the alternatively spliced products that impose a dominant negative effect through the formation of nonproductive complexes with their functional partners

**Abbreviations:** Pcyt2, CTP:phosphoethanolamine cytidyltransferase; PE, phosphatidylethanolamine; EK, ethanolamine kinase; P-Etn, phosphoethanolamine; EPT, CDP-ethanolamine:1,2-diacylglycerol ethanolaminephosphotransferase; PfECT, *Plasmodium falciparum* Pcyt2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GCT, CTP:glycerol-3-phosphate cytidyltransferase; CCT1, CTP:phosphocholine cytidyltransferase 1; HMGCS1, HMG-CoA synthase; LDLR, LDL receptor; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; PCSK9, proprotein convertase subtilisin/kexin type 9; ASM, acid sphingomyelinase.

\* Corresponding author.

E-mail address: [zpavlovi@uoguelph.ca](mailto:zpavlovi@uoguelph.ca) (Z. Pavlovic).


leading to misfolding and degradation of the complexes (Klemm et al., 1998; Li et al., 2012; Mezghrani et al., 2008). According to the GenBank database human and rodent *Pcyt2* genes encode multiple transcripts, which can be recognized as combinations of the internal, 5'-end, and 3'-end splice site variants. The only fully characterized variants are the longest *Pcyt2* $\alpha$  that is produced by canonical splicing, and *Pcyt2* $\beta$  that is produced by skipping of the centrally located Exon 7 in *Pcyt2* $\alpha$  (Poloumienko et al., 2004; Tie and Bakovic, 2007).

Both *Pcyt2* $\alpha$  and  $\beta$  naturally associate as homo- ( $\alpha/\alpha$  and  $\beta/\beta$ ) or heterodimers ( $\alpha/\beta$ ) (Tie and Bakovic, 2007) and dimerization is critical for catalysis by other cytidylyltransferases (Lee et al., 2009; Veitch et al., 1998; Weber et al., 1999). However, all cytidylyltransferases except *Pcyt2* have one catalytic domain, containing the CTP binding motif HXGH. Unique feature of *Pcyt2* is that it has two cytidylyltransferase domains each with its own HXGH motif. Similar to other cytidylyltransferases, the functional role of the N-terminal HXGH motif of *Pcyt2* is assumed to be the CTP binding site (Veitch et al., 1998; Weber et al., 1999). The presence of the second putative catalytic motif has been known since the initial cloning of the yeast, human, rat and murine *Pcyt2* (Bladergroen et al., 1999; Min-Seok et al., 1996; Nakashima et al., 1997; Poloumienko et al., 2004). Two Km values were measured in the kinetic studies of *Pcyt2* partially purified from rat liver implicating that both catalytic motifs contribute to the enzyme


activity (Vermeulen et al., 1994). On the other hand, redundancy of the second catalytic motif was recently reported in a study of *Plasmodium falciparum* *Pcyt2* (Pfect) <sup>419</sup>HIGH motif (Maheshwari et al., 2013).

Here we identify a natural splice variant *Pcyt2* $\gamma$  that is ubiquitously expressed in all adult mouse tissues and in embryonic tissues during development. We establish that *Pcyt2* $\gamma$  is a product of a specific splicing mechanism different from the exon-skipping that leads to the production of *Pcyt2* $\beta$ . *Pcyt2* $\gamma$  is derived by an alternative usage of 5' donor site in Introns 7 and 8 while maintaining the same 3'-acceptor site as in the case of *Pcyt2* $\alpha$ . Consequently, as a derivative of *Pcyt2* $\alpha$ , *Pcyt2* $\gamma$  maintains the first cytidylyltransferase domain including the N-terminal <sup>35</sup>HYGH motif and parts of the central linker region. *Pcyt2* $\gamma$  lacks the second cytidylyltransferase domain including the second CTP binding motif, <sup>244</sup>HIGH, and it is catalytically inactive. However, *Pcyt2* $\gamma$  retains the ability to interact with *Pcyt2* $\alpha$  and to dramatically reduce its homodimerization and enzyme activity. The site-directed mutagenesis of *Pcyt2* $\alpha$  revealed the necessity of both <sup>35</sup>HYGH and <sup>244</sup>HIGH motifs for the catalytic function. Similarly to *Pcyt2* $\gamma$ , *Pcyt2* $\alpha$  mutants were inactive and inhibited *Pcyt2* $\alpha$  activity and homodimerization. Altogether the study demonstrates the importance of both cytidylyltransferase domains for the enzyme function, the critical role of dimerization, and the role of the natural variant *Pcyt2* $\gamma$  to restrain the activity of *Pcyt2* $\alpha$  through dominant-negative interactions.

### A. *Pcyt2* Splicing



### B. *Pcyt2* Proteins



**Fig. 1.** Splicing mechanisms and the structure of the murine *Pcyt2* $\gamma$ . (A) Schematic representation of *Pcyt2* $\alpha$  mRNA (1881 bp) and alternatively spliced variants *Pcyt2* $\beta$  (1486 bp) and *Pcyt2* $\gamma$  (1228 bp); *Pcyt2* $\alpha$  transcript is the longest and is composed of 14 Exons. *Pcyt2* $\beta$  transcript is made by Exon 7 skipping mechanism and retains all other Exons present in *Pcyt2* $\alpha$ ; *Pcyt2* $\gamma$  transcript resembles *Pcyt2* $\alpha$  in sharing Exons 1–6 (blue) and retaining the Exon 7 and Exon 8 (white) sequence. Intron 7 and Intron 8 (not shown) are 428 and 379 bp, respectively. In *Pcyt2* $\gamma$ , alternative 5' donor sites are used in Intron 7 at position 185-GT (red) and Intron 8 at position 259-TT (red) instead of regular splice sites that generated Exon 7 and Exon 8 in *Pcyt2* $\alpha$ . This new type of splicing changed the 3' boundary of the Exon 7 and Exon 8 making them longer. Consequently, *Pcyt2* $\gamma$  has the specific Exon 7a of 238 bp and Exon 8a of 397 bp. Retention of the intron areas (light blue) also introduced a stop codon in Exon 8a at the position 960 and consequently *Pcyt2* $\gamma$  does not maintain the rest of the *Pcyt2* $\alpha$  area including Exons 9–14. Indicated are the positions of the *Pcyt2* $\gamma$ -specific forward primer (Exon 1) and reverse primer (Exon 8a). (B) A schematic representation of *Pcyt2* proteins. *Pcyt2* $\alpha$  and *Pcyt2* $\beta$  contain two cytidylyltransferase catalytic folds in N-terminal domain (21–156 aa; boxed) and C-terminal domain ( $\alpha$ :231–368 aa;  $\beta$ :213–350 aa; boxed). *Pcyt2* $\alpha$  (404 aa) and *Pcyt2* $\beta$  (386 aa) only differ in the length of the central linker segment where 18 amino acids (box) encoded by Exon 7 are absent due to exon skipping in *Pcyt2* $\beta$ . Their cytidylyltransferase folds contain two CTP binding sites,  $\alpha/\beta$ -<sup>35</sup>HYGH in N-domain and  $\alpha$ -<sup>244</sup>/ $\beta$ -<sup>226</sup>HIGH in C-domain. The novel variant *Pcyt2* $\gamma$  (301 aa) maintains the first cytidylyltransferase fold including the N-terminus <sup>35</sup>HYGH motif and parts of the central linker region including the Exon 7 of *Pcyt2* $\alpha$ . *Pcyt2* $\gamma$  lacks the C-terminus cytidylyltransferase domain including the HIGH motif and forms a new C-terminus tail (red) of completely unique composition.

Download English Version:

<https://daneshyari.com/en/article/2816350>

Download Persian Version:

<https://daneshyari.com/article/2816350>

[Daneshyari.com](https://daneshyari.com)